CXCL10 and Alzheimer disease: Results showed that PBMCs can modify the chemokine signature at the BBB level and in particular greatly increase the levels of CCL4 and CXCL10 in endothelial and abluminal cells mimicking BBB [27], highlighting the role of immune system in the onset of AD by disturbing the chemokine expression.